Scheduled Maintenance
We have scheduled some maintenance on Saturday 4th of May 2024 starting from 10AM CEST and could last for 2 hours. During this maintenance we are expecting our website to be unavailable or not fully functional.
BIOMERICA INC (BMRA)
US09061H3075 - Common Stock
Taking everything into account, BMRA scores 2 out of 10 in our fundamental rating. BMRA was compared to 192 industry peers in the Health Care Equipment & Supplies industry. The financial health of BMRA is average, but there are quite some concerns on its profitability. BMRA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BMRA had negative earnings in the past year.
In the past year BMRA has reported a negative cash flow from operations.
BMRA had negative earnings in each of the past 5 years.
BMRA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -61.35%, BMRA is not doing good in the industry: 77.08% of the companies in the same industry are doing better.
BMRA's Return On Equity of -81.26% is on the low side compared to the rest of the industry. BMRA is outperformed by 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.35% | ||
| ROE | -81.26% | ||
| ROIC | N/A |
ROA(3y)-50.76%
ROA(5y)-42.67%
ROE(3y)-65.34%
ROE(5y)-54.99%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 11.40%, BMRA is not doing good in the industry: 82.29% of the companies in the same industry are doing better.
BMRA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for BMRA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 11.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-31.32%
GM growth 5Y-23.17%
2. Health
2.1 Basic Checks
BMRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BMRA has more shares outstanding
The number of shares outstanding for BMRA has been increased compared to 5 years ago.
BMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -4.76, we must say that BMRA is in the distress zone and has some risk of bankruptcy.
BMRA's Altman-Z score of -4.76 is on the low side compared to the rest of the industry. BMRA is outperformed by 69.79% of its industry peers.
BMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.76 |
ROIC/WACCN/A
WACC9.97%
2.3 Liquidity
BMRA has a Current Ratio of 4.44. This indicates that BMRA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.44, BMRA is in the better half of the industry, outperforming 63.54% of the companies in the same industry.
A Quick Ratio of 3.37 indicates that BMRA has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.37, BMRA is doing good in the industry, outperforming 62.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.44 | ||
| Quick Ratio | 3.37 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 28.96% over the past year.
Looking at the last year, BMRA shows a very negative growth in Revenue. The Revenue has decreased by -43.29% in the last year.
Measured over the past years, BMRA shows a decrease in Revenue. The Revenue has been decreasing by -0.80% on average per year.
EPS 1Y (TTM)28.96%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q4.98%
Revenue 1Y (TTM)-43.29%
Revenue growth 3Y-7.24%
Revenue growth 5Y-0.8%
Revenue growth Q2Q-8.38%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BMRA. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BMRA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOMERICA INC
NASDAQ:BMRA (5/3/2024, 7:00:01 PM)
After market: 0.5636 +0 (+0.64%)0.56
-0.04 (-6.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.42M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.35% | ||
| ROE | -81.26% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 11.4% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.44 | ||
| Quick Ratio | 3.37 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)28.96%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-43.29%
Revenue growth 3Y-7.24%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y